Entity family

Browse treatments

Clinical therapies and care approaches used to manage a condition. Examples include immunotherapy, radiotherapy, rehabilitation.

3articles mentioning treatments

5treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: b/tsDMARDs ×

b/tsDMARDs

This treatment is selected. Its supporting articles are shown below.

b/tsDMARDs3

Articles mentioning b/tsDMARDs

3 articles · page 1 of 1

Effects of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcome domains in rheumatoid arthritis: a systematic review and network meta-analyses

rmdopen · abstract · 2026-06-24 · 3 matching annotations

79.9%

b/tsDMARDs b/tsDMARDs Health Assessment Questionnaire rheumatoid arthritis rituximab RA IL-6 inhibitors RA-relevant Janus kinase inhibitors inflammatory arthritis

…sults of this study may help rheumatologists guide selection of b/tsDMARDs, taking into account PROs that are important to the patient or …

Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry

rmdopen · abstract · 2026-06-23 · 1 matching annotations

75.2%

b/tsDMARD b/tsDMARDs b/tsDMARDs rituximab rheumatoid arthritis abatacept TNFi RA IL-6Ri JAKi

…llen joint, while 1942 patients with ≥1 swollen joint started a b/tsDMARD (abatacept: 242, IL-6Ri: 317, JAKi: 333, rituximab: 176, TNFi: …

Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry

rmdopen · abstract · 2026-05-18 · 1 matching annotations

83.9%

b/tsDMARDs b/tsDMARDs rheumatoid arthritis interleukin 6 inhibitors tumour necrosis factor inhibitors CTLA4-Ig Janus kinase (JAK) inhibitors

…eness estimates.Methods We analysed 5462 patients who initiated b/tsDMARDs between 2003 and 2023. RCT ineligibility was defined using comm…